Xencor, Inc. Stock

$8.42

1.45%

Nasdaq, Jul 03, 07:23 pm CET

ISIN

US98401F1057

Symbol

XNCR

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Xencor, Inc. Stock price

$8.42

-24.40 74.34% 5Y

Nasdaq, Closing price Thu, Jul 03 2025

+0.12 1.45%

ISIN

US98401F1057

Symbol

XNCR

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$599.3m

Enterprise Value

$284.1m

Net debt

positive

Cash

$469.6m

Shares outstanding

71.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

4.6 | 5.5

EV/Sales

2.2 | 2.6

EV/FCF

negative

P/B

0.9

Financial Health

Equity Ratio

71.2%

Return on Equity

-34.3%

ROCE

-20.1%

ROIC

Debt/Equity

0.2

Financials (TTM | estimate)

Revenue

$130.4m | $108.3m

EBITDA

$-152.0m | $-193.9m

EBIT

$-163.7m | $-209.4m

Net Income

$-213.0m | $-220.5m

Free Cash Flow

$-173.1m

Growth (TTM | estimate)

Revenue

-19.6% | -2.0%

EBITDA

-21.7% | -16.6%

EBIT

-19.4% | -

Net Income

-59.6% | 5.2%

Free Cash Flow

-450.7%

EPS

$-2.9

FCF per Share

$-2.4

Short interest

17.3%

Employees

250

Rev per Employee

$440.0k

As a Free StocksGuide user, you can view scores for all 6,967 stocks worldwide.

Get Started for Free Today

Xencor, Inc. Stock Analysis

Unlock Scores for Free

??

18 Analysts have issued a Xencor, Inc. forecast:

16x Buy

89%

More details on Analyst Estimates Including Price Targets

18 Analysts have issued a Xencor, Inc. forecast:

Buy

89%

Hold

Sell

Analyst Estimates with Stock Price Targets

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	130 130	20% 20% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	65 65	22% 22% 50%
- Research and Development Expense	229 229	7% 7% 176%
EBITDA	-152 -152	22% 22% -117%
- Depreciation and Amortization	12 12	5% 5% 9%
EBIT (Operating Income) EBIT	-164 -164	19% 19% -126%
Net Profit	-213 -213	60% 60% -163%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Xencor, Inc. Stock News

Neutral

Business Wire

●

2 months ago

Xencor Reports First Quarter 2025 Financial Results

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. “Recently presented interim Phase 1 results support XmAb942 as a hi...

Neutral

Business Wire

●

2 months ago

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammat...

Neutral

Business Wire

●

4 months ago

Xencor Appoints Todd Simpson to Board of Directors

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies an...

More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office	United States
CEO	Bassil Dahiyat
Employees	250
Founded	1997
Website	xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now